Suppr超能文献

I型假性醛固酮增多症中盐皮质激素受体的失活突变。

Inactivating mutations of the mineralocorticoid receptor in Type I pseudohypoaldosteronism.

作者信息

Sartorato P, Khaldi Y, Lapeyraque A-L, Armanini D, Kuhnle U, Salomon R, Caprio M, Viengchareun S, Lombès M, Zennaro M-C

机构信息

INSERM U 478, Faculté de Médecine Xavier Bichat, B.P. 416, 16 rue Henri HUCHARD, 75870 Paris Cedex 18, France.

出版信息

Mol Cell Endocrinol. 2004 Mar 31;217(1-2):119-25. doi: 10.1016/j.mce.2003.10.017.

Abstract

Type I pseudohypoaldosteronism (PHA1) is a rare form of mineralocorticoid resistance characterized by neonatal renal salt wasting and failure to thrive. Typical biochemical features include high levels of plasma aldosterone and renin, hyponatremia and hyperkalemia. Different mutations of the human mineralocorticoid receptor (hMR) gene have been identified in subjects affected by the autosomal dominant or sporadic form of the disease. Our laboratory has investigated a large number of subjects with familial and sporadic PHA1. Several different mutations have been detected, which are localized in different coding exons of the hMR gene. These mutations either create truncated proteins, either affect specific amino acids involved in receptor function. In this paper, we review hMR mutations described to date in PHA1 and their functional characterization. We discuss the absence of mutations in some kindreds and the role of precise phenotypic and biological examination of patients to allow for identification of other genes potentially involved in the disease.

摘要

I型假性醛固酮增多症(PHA1)是一种罕见的盐皮质激素抵抗形式,其特征为新生儿肾性失盐和生长发育不良。典型的生化特征包括血浆醛固酮和肾素水平升高、低钠血症和高钾血症。在患有常染色体显性或散发性该疾病的患者中,已鉴定出人类盐皮质激素受体(hMR)基因的不同突变。我们实验室研究了大量患有家族性和散发性PHA1的患者。已检测到几种不同的突变,这些突变位于hMR基因的不同编码外显子中。这些突变要么产生截短的蛋白质,要么影响受体功能中涉及的特定氨基酸。在本文中,我们综述了迄今为止在PHA1中描述的hMR突变及其功能特征。我们讨论了一些家族中未出现突变的情况,以及对患者进行精确的表型和生物学检查以鉴定可能参与该疾病的其他基因的作用。

相似文献

1
Inactivating mutations of the mineralocorticoid receptor in Type I pseudohypoaldosteronism.
Mol Cell Endocrinol. 2004 Mar 31;217(1-2):119-25. doi: 10.1016/j.mce.2003.10.017.
4
Mineralocorticoid resistance.
Trends Endocrinol Metab. 2004 Aug;15(6):264-70. doi: 10.1016/j.tem.2004.06.003.
9
[Mineralocorticoid resistance: pseudohypoaldosteronism type 1].
Arq Bras Endocrinol Metabol. 2007 Apr;51(3):373-81. doi: 10.1590/s0004-27302007000300004.
10
Clinical and molecular features of type 1 pseudohypoaldosteronism.
Horm Res. 2009;72(1):1-9. doi: 10.1159/000224334. Epub 2009 Jun 30.

引用本文的文献

1
mTORC2 regulates renal tubule sodium uptake by promoting ENaC activity.
J Clin Invest. 2015 Jan;125(1):117-28. doi: 10.1172/JCI73935. Epub 2014 Nov 21.
2
The multifaceted mineralocorticoid receptor.
Compr Physiol. 2014 Jul;4(3):965-94. doi: 10.1002/cphy.c130044.
4
A case of pseudohypoaldosteronism type 1 with a mutation in the mineralocorticoid receptor gene.
Korean J Pediatr. 2011 Feb;54(2):90-3. doi: 10.3345/kjp.2011.54.2.90. Epub 2011 Feb 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验